

=> b reg  
 FILE 'REGISTRY' ENTERED AT 14:13:59 ON 06 MAY 2008  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 5 MAY 2008 HIGHEST RN 1019372-76-9  
 DICTIONARY FILE UPDATES: 5 MAY 2008 HIGHEST RN 1019372-76-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
 predicted properties as well as tags indicating availability of  
 experimental property data in the original document. For information  
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d que sta l11

L6 STR  
 10 9  
 G1 G3  
 ||| |||  
 Cy~N~C~G1~G2~C~Hy~Hy  
 1 2 3 4 5 6 7 8

VAR G1=N/O/S  
 REP G2=(1-2) C  
 VAR G3=O/S  
 NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED  
 ECOUNT IS E5 C E1 N AT 7  
 ECOUNT IS E5 C E1 N AT 8

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE  
 L8 419318 SEA FILE=REGISTRY ABB=ON PLU=ON >=2 NC5/ES  
 L11 101 SEA FILE=REGISTRY SUB=L8 SSS FUL L6

100.0% PROCESSED 177648 ITERATIONS 101 ANSWERS  
 SEARCH TIME: 00.00.02

=> b hcap  
 FILE 'HCAPLUS' ENTERED AT 14:14:11 ON 06 MAY 2008  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is  
 held by the publishers listed in the PUBLISHER (PB) field (available  
 for records published or updated in Chemical Abstracts after December  
 26, 1996), unless otherwise indicated in the original publications.  
 The CA Lexicon is the copyrighted intellectual property of the  
 the American Chemical Society and is provided to assist you in searching  
 databases on STN. Any dissemination, distribution, copying, or storing  
 of this information, without the prior written consent of CAS, is  
 strictly prohibited.

FILE COVERS 1907 - 6 May 2008 VOL 148 ISS 19  
FILE LAST UPDATED: 5 May 2008 (20080505/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate  
substance identification.


=> d bib abs hitrn fhitr 116 tot

LI6 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 AC5 on STN  
 AN 2006:558817 HCAPLUS  
 DR 145:63142  
 II Preparation of amino acid ring-tena derivatives as factor Xa inhibitors  
 IN Song, Yonghong; Zhu, Bing-Tang; Wang, Shumei; Bhakta, Chhaya; Scarbrough,  
 PO Portola Pharmaceuticals, Inc., USA  
 SA PCT Int. Appl., 186 pp.  
 CO CODEN: P18X02  
 DT Patent  
 LA English  
 FAN CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO-2006063113	A2	AT 20060110	2005MO-US0044388	20051207
WO-2006063113	A3	2006010510		
WU AG, AL, AM, AT, AU, BE, BG, BR, BW, BY, BZ, CA, CH,				
CN, CO, CR, CU, CZ, DE, DK, DM, EE, EG, ES, FI, FR, GB,				
GH, GM, GR, HR, HU, ID, IL, IS, JP, KE, KG, KN, KP, KR, KZ,				
LC, LG, LI, LU, LV, MA, MG, MK, MN, MU, MW, MX, MY,				
NI, NG, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG,				
SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UG, US, VE, VC,				
VN, YU, ZA, ZM, ZW				
RW AG, BE, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU,				
EE, IT, LT, LU, LV, MC, NL, PE, PI, PO, RS, SI, SK, TR, RF, RJ,				
CF, CG, CI, CM, CA, GN, GO, ML, MR, NE, SN, TD, TG, BM, GH,				
GM, RE, LS, MM, ME, NA, SD, SE, TC, UG, ZM, ZW, AM, AZ, AY,				
BG, BS, BR, BU, BV, TW, JM, JI, CA, EP, OA				
US-20060160821	A1	20060720	2005US-000298317	20051207
PPRAI 2004-00634201P	P	20041207		
AS MARPAT 15:63142				
OS The invention relates to urea derivs. A-O-D-(CR7R8)(NR6)NCOC(R4)SR3CONR1P 2, n, m are 0 or 1; D is a direct bond, alkyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocyclic, heterobicyclic; Q is a direct bond, alkylene, CO, CS, O, S, imino, SO2, SO, etc. (at least one of D and Q is not a direct bond); A is and the pharmacologically acceptable salts, pyridyl oxide, etc.; R1 is H, alkyl, arylalkyl, heteroaryl, alkenyl; R2 is (un)substituted arylalkyl, arylalkoxyalkyl, heteroaryl, cycloalkyl, etc.; R3 is H, (un)substituted alkyl, alkene, cycloalkyl, etc.; or R4 may come from a ring with R5 or R6) and the pharmaceutically acceptable salts and prodrugs which are inhibitors of Factor Xa and are used to prevent or treat a number of conditions characterized by undesired thrombolysis. Thus, the compound (4-chlorophenyl)-N-(1-((R)-2-(1-methyl(4,4'-bipiperidin-1-yl)-2-oxo-1-phenylethyl)-CA INDEXT NAME)				
IT 855524-53-P				
RI: PAC (Pharmacological activity); SPH (Synthetic preparation); THU (Therapeutic use); BIOLO (Biological study); PREP (Preparation); USES (Use) (Preparation of medical area urea derivs. as factor Xa inhibitors)				
IT 855524-53-P				
RI: PAC (Pharmacological activity); SPH (Synthetic preparation); THU (Therapeutic use); BIOLO (Biological study); PREP (Preparation); USES (Use) (Preparation of medical area urea derivs. as factor Xa inhibitors)				
RN 855524-53-P				
CN US-2004-00634201P				


Absolute stereochemistry.

L16 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L16 ANSWER 2 OF 2 HCAPULS COPYRIGHT 2008 ACS ON STN  
 AR 20057140568 HCAPULS  
 DN 143:78008  
 II Preparation of urea/carbamate derivatives as inhibitors of coagulation  
 preparation for treatment of thromboembolic diseases  
 IN Cernanne, Bertram; Dorsch, Dieter; Mederski, Werner; Tsaklakidis, Christos;  
 Gietz, Johannes  
 PA Marx Patent G.m.b.H., Germany  
 SO PCT Int. Appl., 80 pp.  
 CODEN: PEXXXX  
 DT Patent  
 LA German  
 FAN.CNT 1

PI	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	WO/000506528	A1	20050626	200404WPO-0013202	20041119
FI	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, DE, CE, DE, DK, EE, EG, ES, FI, GB, GD, GE, GR, GU, HK, HU, IL, IN, JP, KE, KG, KH, KR, KZ, LA, LB, LG, LI, LU, LV, MA, MG, MK, MN, MW, MX, ME, NA, NI, NL, NO, NE, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VE, VN, YU, ZA, ZM, ZW				
	RM: BW, GB, GM, KE, LS, MW, ME, NA, NI, NL, NO, NE, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VE, VN, YU, ZA, ZM, ZW				
	AE, BG, BY, KE, EG, ES, FI, GB, GD, GE, GR, GU, HK, HU, IL, IN, JP, KE, KG, KH, KR, KZ, LA, LB, LG, LI, LU, LV, MA, MG, MK, MN, MW, MX, ME, NA, NI, NL, NO, NE, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VE, VN, YU, ZA, ZM, ZW				
	SE, SI, SK, TR, TF, BF, CF, CE, CI, CM, CA, GN, GD, GW, ML, MR, NE, SH, TN, TG				
	DE--200558339	A1	20050707	2003DE--100056539	20031215
	UA--2004296956	A1	20050623	2004UA--200029696	20041119
	CA--2549548	A1	20050623	2004CA--002549548	20041119
	DE--1694663	A1	20060830	2004DE--001694663	20041119
	R: AT, BE, CH, CN, DK, ES, FR, GB, GR, HU, IL, IN, JP, KE, KG, KR, KZ, LA, LB, LG, LI, LU, LV, MA, MG, MK, MN, MW, MX, ME, NA, NI, NL, NO, NE, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VE, VN, YU, ZA, ZM, ZW				
	EP--2004290216	A	20070110	2004CA--00036500	20041119
	BR--2004071753	A	20070306	2006BR--00071753	20061119
	JP--2005733987	A	20070531	2006JP--000544246	20061119
	IN--2006061558	A	20070504	2006IN--R00001578	20060608
	US--200606939	A	20060731	2006US--0006939	20060819
	US--2007012370	A1	20070531	2006US--00052870	20060614
	US--2007005839	A	20071215		
PR	200400-EP0013211	W			
OSAI	CSACREACT 143:78086; MARPAT 143:78086				



AB Title compounds, R<sup>1</sup> = halo, alkoxyl, etc.; Y = amino, O; Y = O, S, amino, etc.; R<sup>2</sup> = H, aryl, heteroaryl, etc.; E = CH, N; Z<sup>1</sup>, Z<sup>2</sup> = acyl, etc.; Q = O, amino, acyl, etc.; R<sup>4</sup>-4' = A, OH, alkyl; T = (hetero)cyclyl, etc. are prepared. For instance, (R)-N-(4-chlorophenyl)-N'-[2-(1,4-bis(oxophenyl)-2-phenyl)-1-yl]-2-oxo-1-phenylethyl-1-yl]-2-oxo-1-phenylethyl-1-yl]-2-oxo-1-phenylethyl-1-yl] (II) is prepared in 3 steps from 1-methyl-4,4'-bipiperidinyl-1-yl)-N-(tert-butoxycarbonyl)phenylglycine and 4-chlorophenylisocyanate. II has IC<sub>50</sub> = 6 × 10<sup>-6</sup> M for Factor Xa. It is an inhibitor of coagulation factor Xa and can be used for the prophylaxis and/or for the treatment of thromboembolic diseases and for treating tumors.

II 855524-53-7p, (R)-N-(4-chlorophenyl)-N'-[2-(1-methyl-4,4'-bipiperidinyl-1-yl)-2-oxo-1-phenylethyl-1-yl]-2-oxo-1-phenylethyl-1-yl]-2-oxo-1-phenylethyl-1-yl]-N-(4-chlorophenyl) hydrochloride 855524-90-2p, (R)-N-[2-(1,4'-[Bipiperidinyl-1-yl]-1-(4-hydroxyphenyl)-2-oxoethyl)-N-(4-chlorophenyl) hydrochloride 855524-90-2p, (R)-N-[2-(1,4'-[Bipiperidinyl-1-yl)-2-oxo-1-(thiophen-2-yl) ethyl]-N-(4-chlorophenyl) hydrochloride 855524-93-5p, (R)-N-(4-chlorophenyl)-N'-[1-(4-methoxyphenyl)-2-(1-methyl-4,4'-bipiperidinyl-1-yl)-2-oxo-1-phenylethyl]-2-oxo-1-phenylethyl-1-yl]-2-oxo-1-phenylethyl-1-yl] 85554-95-7p, (R)-N-(4-chlorophenyl)-N'-[2-(1-methyl-4,4'-bipiperidinyl-1-yl)-2-oxo-1-

16 ANSWER 2 OF 2 NCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)  
(thiophen-2-yl)ethylurea trifluorocarbamate 855524-98-0P,  
*N*-[2-(1,4'-bipiperidinyl-1'-yl)-1-(4-hydroxyphenyl)-2-oxoethyl]-*N'*-(4,4'-bipiperidinyl-1'-yl)-2-oxo-1-phenylethylurea trifluorocarbamate 855525-19-9P,  
*N*-[2-(1,4'-bipiperidinyl-1'-yl)-2-oxo-1-phenylethylurea trifluorocarbamate 855525-14-3P, (*R*)-*N*-(2-{(1,4'-bipiperidinyl-1'-yl)-2-oxo-1-phenylethyl}-1-yl)-2-chlorophenylcarbamate 855525-19-9P, (*R*)-*N*-(4-Chlorophenyl)-*N'*-(2-[1-methyl-4,4'-bipiperidinyl-1-yl]-2-oxo-1-(2-chlorophenyl)ethyl)urea trifluoroacetate 855525-20-1P, (*R*)-*N*-(4-Chlorophenyl)-*N'*-(2-[1,4,4'-bipiperidinyl-1-yl]-2-oxo-1-(2-chlorophenyl)ethyl)urea trifluoroacetate 855525-22-3P  
855525-23-4P, 4-Chlorophenylcarbamic acid  
(*R*)-(2-[1-methyl-4,4'-bipiperidinyl-1-yl]-2-oxo-1-phenylethyl ester trifluoroacetate 855525-24-5P, 4-Chlorophenylcarbamic acid  
(*R*)-(2-[1-methyl-4,4'-bipiperidinyl-1-yl]-2-oxo-1-phenylethyl ester trifluoroacetate 855525-27-8P, 4-Chlorophenylcarbamic acid (*R*)-(2-[1,4,4'-bipiperidinyl-1-yl]-1-(2-chlorophenyl)-2-oxoethyl ester trifluoroacetate 855525-28-9P, 4-Chlorophenylcarbamic acid  
(*R*)-(2-[1,4,4'-bipiperidinyl-1-yl]-2-oxo-1-phenylethyl ester hydrochloride 855525-30-3P, 4-Chlorophenylcarbamic acid (*R*)-(2-[2-chlorophenyl]-2-methyl-4,4'-bipiperidinyl-1-yl)-2-oxo-1-phenylethyl ester trifluoroacetate 855525-34-7P, 4-Chlorophenylcarbamic acid (*R*)-(1,4'-bipiperidinyl-1-yl)-1-(2-chlorophenyl)-2-oxoethyl ester trifluoroacetate 855525-38-4P, 4-Chlorophenylcarbamic acid  
(*R*)-(2-[1-methyl-4,4'-bipiperidinyl-1-yl]-2-oxo-1-phenylethyl ester trifluoroacetate 855525-47-2P, 4-Chlorophenylcarbamic acid  
(*R*)-(2,3-difluorophenyl)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxoethyl ester trifluoroacetate 855525-48-3P, 4-Chlorophenylcarbamic acid  
(*R*)-(1-(2-fluorophenyl)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxoethyl ester 855525-49-4P, 4-Chlorophenylcarbamic acid  
(*R*)-(1-(2-methoxyphenyl)-2-(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxoethyl ester trifluoroacetate 855525-50-1P, 4-Chlorophenylcarbamic acid  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses).  


```
[prep. of urea/carbamate derivs. as inhibitors of coagulation factor Xa for treatment of thromboembolic disorders]
```

  
IT 855524-53-7P, (*R*)-*N*-(4-Chlorophenyl)-*N'*-(2-[1-methyl-4,4'-bipiperidinyl-1-yl]-2-oxo-1-phenylethyl)urea  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses).  

```
[prep. of urea/carbamate derivs. as inhibitors of coagulation factor Xa for treatment of thromboembolic disorders]
```

  
RN 855524-53-7P, NCAPLUS  
CN Urea, *N*-(4-chlorophenyl)-*N'*-(2-[(1'-methyl-4,4'-bipiperidinyl-1-yl)-2-oxo-1-phenylethyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 12      THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d bib abs hitstr 1167 tot  
L167 NOT FOUND
```



The L-number entered has not been defined in this session, or it has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (=>).

```
=> d bib abs hitstr 117 tot
```

L17 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN  
 RN 2007:1120606 HCAPLUS  
 DN 147:406845  
 TI Preparation of diazaheterocycles as calcitonin gene related peptide  
 receptor antagonists for treating migraine and other conditions  
 IN Chen, Ling; Chaturvedula, Prasad V.; Civiello, Rita; Degnan, Andrew P.;  
 Dubowchik, Gene M.; Han, Xiaojun; Jiang, Xiang Jun J.; Karageorge, George  
 M.; Luo, Guanglin; Macor, John E.; Poindexter, Graham S.; Tora, George O.  
 PA Bristol-Myers Squibb Company, USA  
 SO U.S. Pat. Appl. Publ., 215pp., Cont.-in-part of U.S. Ser. No. 729,155.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN CNT 4  

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US-20070232600	A1	20071004	2007US-000620291	20070105
US-----7314883	B2	20080101		
US-20040204397	A1	20040104	2003US-000729155	20031205
US-----7220862	B2	20070522		
PRAI 2003US-000729155	A2	20031205		
2002US-00386138P	P	20020605		
2002US-00388617P	P	20020613		
2002US-00389870P	P	20020619		
2002US-00393200P	P	20020701		
2002US-00413534P	P	20020925		
2003US-000445523	A2	20030527		


 OS MARPAT 147:406845  
 GI



AB Diazaheterocycles I [m, n = 0-2; V = (un)substituted NH<sub>2</sub>, OH; Q = (un)substituted alkyl, NH<sub>2</sub>, NHC(=O)H, NHC(=O)NH<sub>2</sub>; U = CH<sub>2</sub>, NH; D = O, NCN, alkylsulfonylimino; A = C, N, CH; E = (un)substituted heterocyclic; with provisos] were prepared for use as antagonists of calcitonin gene-related peptide receptors for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). Thus, the indazole II was prepared from 1H-indazole-5-carbaldehyde and had IC<sub>50</sub> for calcitonin gene related peptide receptor binding of  $\leq 10$  nM.  
 IT 635711-71-6P 635711-72-7P 635711-73-8P  
 635711-75-0P 635711-76-1P 635711-77-2P  
 635711-78-3P 635711-79-4P 635711-80-7P  
 635711-82-9P 635711-83-0P 635711-84-1P  
 635711-86-3P 635711-87-4P 635711-88-5P  
 635711-89-6P 635711-90-9P 635711-91-0P

L17 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)  
 635711-92-1P 635711-93-2P 635711-94-3P  
 635711-95-4P 635711-96-5P 635711-97-6P  
 635711-98-7P 635711-99-8P 635712-00-4P  
 635712-01-5P 635712-02-6P 635712-04-8P  
 635712-05-9P 635712-08-2P 635712-09-3P  
 635712-10-6P 635712-11-7P 635712-12-8P  
 635712-13-9P 635712-14-0P 635712-15-1P  
 635712-16-2P 635712-17-3P 635712-19-5P  
 635712-20-8P 635712-22-0P 635712-23-1P  
 635712-24-2P 635712-25-3P 635712-26-4P  
 635712-27-5P 635712-28-6P 635712-29-7P  
 635712-30-0P 635712-31-1P 635712-32-2P  
 635712-33-3P 635712-34-4P 635712-35-5P  
 635712-38-8P  
 RU: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of diazaheterocycles as calcitonin gene related peptide receptor antagonists for treating migraine and other diseases)  
 RN 635711-71-6 HCAPLUS  
 CN Urea, N-[(1S)-1-[(1,4'-bipiperidin)-1'-ylcarbonyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-2-naphthalenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-72-7 HCAPLUS  
 CN Urea, N-[(1S)-1-[(1,4'-bipiperidin)-1'-ylcarbonyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-2-phenoxypheyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635711-73-8 HCAPLUS  
 CN Urea, N-[(1S)-1-[(1,4'-bipiperidin)-1'-ylcarbonyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-1-naphthalenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-75-0 HCAPLUS  
 CN Urea, N-[(1S)-1-[(1,4'-bipiperidin)-1'-ylcarbonyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4,5-trimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635711-76-1 HCAPLUS  
 CN Urea, N-[(1S)-1-[(1,4'-bipiperidin)-1'-ylcarbonyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-77-2 HCAPLUS  
 CN Urea, N-[(1S)-1-[(1,4'-bipiperidin)-1'-ylcarbonyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 635711-78-3 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(3-ethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-79-4 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-phenyl- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 635711-80-7 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(4-phenoxyphe- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-82-9 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(4-phenoxyphe- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 635711-83-0 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(3-acetylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-84-1 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(2,3-dichlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 635711-86-3 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(2-methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-87-4 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(3-methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




L17 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)



RN 635711-97-6 HCAPLUS  
 CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-(trifluoromethyl)phenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-98-7 HCAPLUS  
 CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dichlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)



RN 635712-01-5 HCAPLUS  
 CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,6-dichloro-4-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-02-6 HCAPLUS  
 CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,5-dimethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)



RN 635711-99-8 HCAPLUS  
 CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-(1-methylethyl)phenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-00-4 HCAPLUS  
 CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,6-difluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)







RN 635712-04-8 HCAPLUS  
 CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-chloro-5-(trifluoromethyl)phenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-05-9 HCAPLUS  
 CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3,4-trifluorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.




L17 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 635712-16-2 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-bromophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-17-3 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-fluorophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 635712-19-5 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-methoxyphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-20-8 HCAPLUS  
 CN Benzoic acid, 4-[[[(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]amino]carbonylamino]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 635712-22-0 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-difluorophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-23-1 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(5-chloro-2-methoxyphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 635712-24-2 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-4-methylphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-25-3 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(5-chloro-2-methoxyphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635712-26-4 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chloro-2-(trifluoromethyl)phenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-27-5 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-ethoxyphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635712-28-6 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-ethylphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-29-7 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chloro-2-methylphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635712-30-0 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-2-methylphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-31-1 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-4-fluorophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635712-32-2 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-bromo-2-methylphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-33-3 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(5-fluoro-2-methylphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635712-34-4 HCAPLUS  
 CN Benzoic acid, 3-[[[(1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl]amino]carbonylamino]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-35-5 HCAPLUS  
 CN Urea, N-[[1,1'-biphenyl]-2-yl-N'-[[1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635712-38-8 HCAPLUS  
 CN Urea, N-[[1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl]-N'-(2-(trifluoromethoxy)phenyl)- (CA INDEX NAME)



Absolute stereochemistry.



RE.CNT 119 THERE ARE 119 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN

AN 2007:705719 HCAPLUS  
 DN 147:118256  
 TI Preparation of piperidine-1-carboxamide derivatives and spirocycles thereof as antagonists of calcitonin gene-related peptide receptors  
 IN Chaturvedi, Prasad V.; Chen, Ling; Civiello, Rita; Degnan, Andrew P.; Dubowchik, Gene M.; Han, Xiaojun; Jiang, Xiang Jun J.; Macor, John E.; Poindexter, Graham S.; Tora, George O.; Luo, Guanglin  
 PA Bristol-Myers Squibb Company, USA  
 SO U.S. Pat. Appl. Publ., 198pp., Cont.-In-part of U.S. Ser. No. 729,155. CODEN: USXXCO  
 DT Patent  
 LA English  
 FAR.CTY 4  
 PATENT NO. KIND DATE APPLICATION NO. DATE  
 PI US-20070149502 A1 20070628 2007US-000620308 20070105  
 US-20040204397 A1 20041014 2003US-000729155 20031205  
 US-----7220862 B2 20070522  
 PRA1 2003US-000729155 A2 20031205  
 2002US-00386138P P 20020605  
 2002US-00388617P P 20020613  
 2002US-00389870P P 20020619  
 2002US-00393200P P 20020701  
 2002US-00413534P P 20020925  
 2003US-000445523 A2 20030527  
 OS  
 CI MARPAT 147:118256



AB The title comps. [I; V = N(R1)(R2) or OR4; R4 = H, C1-6 alkyl, C1-4 haloalkyl, etc.; R1, R2 = independently H, each (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, -C1-6alkyleneamino(C1-3alkyl)2, C3-7 cycloalkyl, Ph, azetidyl, adamantyl, tetrahydrofuranyl, furanyl, dioxolanyl, thienyl, tetrahydrothienyl, pyrrolidyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, imidazolidinyl, imidazolidinyl, etc.; R1 and R2 optionally and independently contain 1 or 2 carbonyls or optionally and independently interrupted from the nitrogen to which C1-3 alkylene or C1-3 alkylidene; or NR1R2 together form each (un)substituted azetidyl, pyrrolidyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, imidazolidinyl, pyrazolidinyl, pyrazolidinyl, azepinyl, or spirocyclic ring, etc.; Q = (sy)sR3, NH(sy)sR3, NHC(O)(sy)sR3, NHC(O)O(sy)sR3, NHC(O)NH(sy)sR3, O(sy)sR3, (sy)sNHR3, etc.; wherein sy = C1-3 alkylene or C1-3 alkylidene; s = 0 or 1; U = CH2, NH; R3 = (i) heterocycle having two 5 to 7 membered fused rings, (ii) 4 to 6 membered heterocycle containing 1-3 heteroatoms selected from O, N and S optionally containing 1 to 2 carbonyls, (iii) C3-7 cycloalkyl, etc.; D = O, N(CN) or N(SO2-C1-3 alkyl); A = C, m, n = 1; E = N, CH, C; p = 0; G, J and E together form a fused heterocycle having two 5- to 7-membered fused rings optionally containing 1 or 2 carbonyls or pharmaceutically acceptable salts thereof are prepared. These comps. are antagonists of calcitonin gene-related peptide receptors (CGRP receptor) and are useful in therapy for treatment of neurogenic

L17 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)

vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing assocd. with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors. Thus, (R)-2-[[[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)piperidin-1-yl]carbonylamino]-3-[[1-[[2-(trimethylsilyl)ethyl]sulfonyl]-1H-indazol-5-yl]propionic acid was condensed with 4-piperidinopiperidine using PyBOP in CH2Cl2 at room temp. for 16 h followed by treatment with CsF at 80° in MeCN to give (R)-4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)piperidine-1-carboxylic acid [2-(1,4'-bipiperidinyl-1'-yl-1-(1H-indazol-5-ylmethyl)-2-oxoethyl]amide (II). II showed IC50 of ≤10 nM for inhibiting the binding of [125I]CGRP to homogenate of SK-NMC cells.


IT 635711-71-6P 635711-72-7P 635711-73-8P  
 635711-75-0P 635711-76-1P 635711-77-2P  
 635711-78-3P 635711-79-4P 635711-80-7P  
 635711-82-9P 635711-83-0P 635711-84-1P  
 635711-86-3P 635711-87-4P 635711-88-5P  
 635711-89-6P 635711-90-9P 635711-91-0P  
 635711-92-1P 635711-93-2P 635711-94-3P  
 635711-95-4P 635711-96-5P 635711-97-6P  
 635711-98-7P 635711-99-8P 635712-00-4P  
 635712-01-5P 635712-02-6P 635712-04-8P  
 635712-05-9P 635712-08-2P 635712-09-3P  
 635712-10-6P 635712-11-7P 635712-12-8P  
 635712-13-9P 635712-14-0P 635712-15-1P  
 635712-16-2P 635712-17-3P 635712-19-5P  
 635712-20-8P 635712-22-0P 635712-23-1P  
 635712-24-2P 635712-25-3P 635712-26-4P  
 635712-27-5P 635712-28-6P 635712-29-7P  
 635712-30-0P 635712-31-1P 635712-32-2P  
 635712-33-3P 635712-34-4P 635712-35-5P  
 635712-38-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of piperidine-1-carboxamide derivs. and spirocyclic comps. thereof as antagonists of calcitonin gene-related peptide receptors)

RN 635711-71-6 HCAPLUS  
 CN Urea, N-[[1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl]-N'-(2-naphthalenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-72-7 HCAPLUS  
 CN Urea, N-[[1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl]-N'-(2-phenoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 635711-73-8 HCAPLUS  
 CN Urea, N-([(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-1-naphthalenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-75-0 HCAPLUS  
 CN Urea, N-([(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4,5-trimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 635711-76-1 HCAPLUS  
 CN Urea, N-([(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-77-2 HCAPLUS  
 CN Urea, N-([(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 635711-78-3 HCAPLUS  
 CN Urea, N-([(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-ethyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 635711-79-4 HCAPLUS  
 CN Urea, N-([(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



L17 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 635711-80-7 HCAPLUS  
 CN Urea, N-([(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-acetylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.







RN 635711-82-9 HCAPLUS  
 CN Urea, N-([(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-phenoxypheyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 635711-83-0 HCAPLUS  
 CN Urea, N-([(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-phenoxypheyl)- (CA INDEX NAME)

Absolute stereochemistry.




L17 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 635711-95-2 HCAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-difluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-94-3 HCAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-95-4 HCAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,4-dimethylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




L17 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 635711-98-7 HCAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dichlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-99-8 HCAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-(1-methylethyl)phenyl)- (CA INDEX NAME)

Absolute stereochemistry.




L17 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 635711-96-5 HCAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,5-dichlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-97-6 HCAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-(trifluoromethyl)phenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-97-7 HCAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-(trifluoromethyl)phenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-97-8 HCAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-(trifluoromethyl)phenyl)- (CA INDEX NAME)


Absolute stereochemistry.




RN 635712-00-4 HCAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,6-difluorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.




L17 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RN 635712-02-6 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,5-dimethoxyphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-04-8 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-chloro-5-(trifluoromethyl)phenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RN 635712-09-3 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-chlorophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-10-6 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dichlorophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RN 635712-05-9 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3,4-trifluorophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-08-2 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-fluorophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RN 635712-11-7 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dimethoxyphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-12-8 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-ethoxyphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635712-13-9 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-bromophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-14-0 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-fluorophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635712-15-1 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chlorophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-16-2 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-bromophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635712-17-3 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-fluorophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-19-5 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-methoxyphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635712-20-8 HCAPLUS  
 CN Benzoic acid, 4-[[[(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-22-0 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-difluorophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 635712-23-1 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(2,4-dimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-24-2 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(3-chloro-4-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 635712-25-3 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(5-chloro-2-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-26-4 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(4-chloro-2-(trifluoromethyl)phenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 635712-27-5 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(4-ethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-28-6 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(4-ethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 635712-29-7 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(4-chloro-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-30-0 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(3-chloro-2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635712-31-1 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-4-fluorophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-32-2 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-bromo-2-methylphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635712-33-3 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(5-fluoro-2-methylphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-34-4 HCAPLUS  
 CN Benzoic acid, 3-[[[(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]amino]carbonyl]amino]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635712-35-5 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-bromo-2-methylphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-38-8 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-(trifluoromethoxy)phenyl)]- (CA INDEX NAME)

Absolute stereochemistry.

L17 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




L17 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON STM


AN 2006:578214 HCAPLUS  
DN 145:63144  
TI Preparation of amino acid thiourea derivatives as factor Xa inhibitors  
IN Song, Yonghong; Zhu, Bing-Yan; Bhakta, Chhaya; Scarborough, Robert M.  
PA Portola Pharmaceuticals, Inc., USA  
SO PCT Int. Appl., 72 pp.  
CODEN: PIKX22  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO--2006063293	A2	20060615	2005WO-US0044739	20051207
WO--2006063293	A3	20070712		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, ME, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
Fw: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, ME, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US-20060160790	A1	20060720	2005US-000298296	20051207
PRAI 2004US-00634150P	P	20041207		
OS MARPAT 145:63144				
AB The invention relates to thiourea derivs. A-Q-D-(CH <sub>7</sub> R <sub>8</sub> )n(NR <sub>6</sub> )nCOCRA <sub>5</sub> NR <sub>3</sub> C(S)NR <sub>1</sub> R <sub>2</sub> [m, n are 0 or 1; D is a direct bond, (un)substituted aryl, heteroaryl, cycloalkylene, heteromonocyclyl, heterobicycyl; Q is a direct bond, alkylene, CO, CS, O, S, imino, SO <sub>2</sub> , SO, etc. (at least one of D and Q is not a direct bond); A is amino, amidino, guanidino groups, alkyl, pyridyl oxide, etc.; R <sub>1</sub> is H, alkyl, arylalkyl, heteroaryl, alkenyl; R <sub>2</sub> is (un)substituted arylalkyl, arylcycloalkyl, heteroaryl, cycloalkyl, etc.; R <sub>3</sub> -R <sub>8</sub> are H, (un)substituted alkyl, alkenyl, etc.; or R <sub>4</sub> may from a ring with R <sub>5</sub> or R <sub>6</sub> ] and their pharmaceutically-acceptable salts and prodrugs which are inhibitors of Factor Xa and are used to prevent or treat a number of conditions characterized by undesired thrombosis. Thus, p-MeCNC:(NH) <sub>2</sub> CHC <sub>6</sub> H <sub>4</sub> NHCOCH <sub>2</sub> PhNH <sub>2</sub> (S)NHCOCH <sub>2</sub> Ph was prepared by reaction of Boc-protected phenylglycine with 4-aminobenzonitrile, iodomethane, dimethylamine, and 4-bromophenyl isocyanate. The product showed IC <sub>50</sub> ≤ 100 nM for inhibition of factor Xa.				
IT 890524-22-BP RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of amino acid thiourea derivs. as factor Xa inhibitors)				
RN 890524-22-8 HCAPLUS CN Thiourea, N-(4-chlorophenyl)-N'-[1-(2-methyl[4,4'-bipiperidin]-1-yl)-2-oxo-1-phenylethyl]- (CA INDEX NAME)				


Absolute stereochemistry.



L17 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON STM (Continued)  
CN Urea, N-(4-chlorophenyl)-N'-[1-(2-fluorophenyl)-2-oxo-2-(2-oxo[1,4'-bipiperidin]-1'-yl)ethyl]- (CA INDEX NAME)



RN 891789-80-3 HCAPLUS  
CN Urea, N-(4-chlorophenyl)-N'-[1-(2-methoxyphenyl)-2-oxo-2-(2-oxo[1,4'-bipiperidin]-1'-yl)ethyl]- (CA INDEX NAME)




L17 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON STM

AN 2006:558817 HCAPLUS  
DN 145:63142  
TI Preparation of amino acid urea derivatives as factor Xa inhibitors  
IN Song, Yonghong; Zhu, Bing-Yan; Wang, Shumei; Bhakta, Chhaya; Scarborough, Robert M.  
PA Portola Pharmaceuticals, Inc., USA  
SO PCT Int. Appl., 186 pp.  
CODEN: PIKX22  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO--2006063113	A2	20060615	2005WO-US0044328	20051207
WO--2006063113	A3	20070510		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, ME, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
Fw: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, ME, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US-20060160821	A1	20060720	2005US-000298317	20051207
PRAI 2004US-00634201P	P	20041207		
OS MARPAT 145:63142				
AB The invention relates to urea derivs. A-Q-D-(CH <sub>7</sub> R <sub>8</sub> )n(NR <sub>6</sub> )nCOCRA <sub>5</sub> NR <sub>3</sub> CONR <sub>1</sub> R <sub>2</sub> [m, n are 0 or 1; D is a direct bond, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heteromonocyclyl, heterobicycyl; Q is a direct bond, alkylene, CO, CS, O, S, imino, SO <sub>2</sub> , SO, etc. (at least one of D and Q is not a direct bond); A is amino, amidino, guanidino groups, alkyl, pyridyl oxide, etc.; R <sub>1</sub> is H, alkyl, arylalkyl, heteroaryl, alkenyl; R <sub>2</sub> is (un)substituted arylalkyl, arylcycloalkyl, heteroaryl, cycloalkyl, etc.; R <sub>3</sub> -R <sub>8</sub> are H, (un)substituted alkyl, alkenyl, cycloalkyl, etc.; or R <sub>4</sub> may from a ring with R <sub>5</sub> or R <sub>6</sub> ] and their pharmaceutically-acceptable salts and prodrugs which are inhibitors of Factor Xa and are used to prevent or treat a number of conditions characterized by undesired thrombosis. Thus, N-[(4-chlorophenyl)amino]carbonyl-glycine [4-(3-methyl-4,5-dihydro-1H-indazol-2-yl)phenyl]amide was prepared by reaction of Boc-protected glycine with 4-aminobenzonitrile, iodomethane, N-methylethylenediamine, and 4-chlorophenyl isocyanate. The product showed IC <sub>50</sub> ≤ 100 nM for inhibition of factor Xa.				
IT 891789-71-2P 891789-79-OP 891789-80-3P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of amino acid urea derivs. as factor Xa inhibitors)				
RN 891789-71-2 HCAPLUS CN Urea, N-(4-chlorophenyl)-N'-[1-(R)-2-oxo-2-(2-oxo[1,4'-bipiperidin]-1'-yl)-1-phenylethyl]- (CA INDEX NAME)				

Absolute stereochemistry.



RN 891789-79-0 HCAPLUS

L17 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON STM

AN 2005:638773 HCAPLUS  
DN 143:133401  
TI Preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists  
IN Deegan, Andrew P.; Chen, Ling; Civiello, Rita; Dubowchik, Gene M.; Han, Xiaojun; Jiang, Xianqun J.; Macor, John E.; Tora, George  
PA Bristol-Myers Squibb Company, USA  
SO PCT Int. Appl., 385 pp.  
CODEN: PIKX22  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO--2005065779	A1	20050721	2003WO-US0038799	20031205
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
Fw: BW, GM, GR, KE, LS, MW, ME, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AE, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA--2549330	A1	20050721	2003CA-002549330	20031205
AU--2003297694	A1	20050812	2003AU-00297694	20031205
EP--1689493	A1	20060816	2003EP-000819270	20031205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LT, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR--2003018637	A	20070213	2003BR-000018637	20031205
CN--1917921	A	20070223	2003CN-080111030	20031205
JP--2007524568	T	20070830	2005JP-000513137	20031205
IN--2006DN02822	A	20070803	2006IN-DN002822	20060518
MX--2006PA06070	A	20060719	2006MX-PA0006070	20060529
NO--2006002648	A	20060802	2006NO-00002648	20060608
PRAI 2003EP-000819270	A	20031205		
2003WO-US0038799	W	20031205		
OS MARPAT 143:133401				
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Diazaheterocycles I [m, n = 0-2; V = (un)substituted NH<sub>2</sub>, OH; Q = (un)substituted alkyl, NH<sub>2</sub>, NHCO<sub>2</sub>H, NHCONH<sub>2</sub>; U = CH<sub>2</sub>, NH; D = O, NCN, alkylsulfonylimino; A = C, N, CH; E = (un)substituted heterocyclic; with proviso] were prepared for use as antagonists of calcitonin gene-related peptide receptors for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). E.g., a multi-step synthesis of II which had IC<sub>50</sub> for calcitonin gene related peptide receptor binding of ≤ 10 nM, was given. The pharmaceutical composition comprising the compound I is claimed.

IT 635711-71-6P 635711-72-7P 635711-73-8P  
635711-75-0P 635711-76-1P 635711-77-2P  
635711-78-3P 635711-79-4P 635711-80-7P  
635711-82-9P 635711-83-0P 635711-84-1P  
635711-86-3P 635711-87-4P 635711-88-5P  
635711-89-6P 635711-90-9P 635711-91-0P  
635711-92-1P 635711-93-2P 635711-94-3P  
635711-95-4P 635711-96-5P 635711-97-6P  
635711-98-7P 635711-99-8P 635712-00-4P  
635712-01-5P 635712-02-6P 635712-04-8P  
635712-05-9P 635712-06-2P 635712-09-3P  
635712-10-6P 635712-11-7P 635712-12-8P  
635712-13-9P 635712-14-0P 635712-15-1P  
635712-16-2P 635712-17-3P 635712-19-5P  
635712-20-8P 635712-22-0P 635712-23-1P  
635712-24-2P 635712-25-3P 635712-26-4P  
635712-27-5P 635712-28-6P 635712-29-7P


L17 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)

635712-30-8P 635712-31-1P 635712-32-2P  
635712-33-3P 635712-34-4P 635712-35-5P  
635712-38-8PRL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)  
(prepn. of diazaheterocycles as calcitonin gene related peptide  
receptor antagonists)

RN 635711-71-6 HCAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-  
3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-naphthalenyl)- (CA  
INDEX NAME)


Absolute stereochemistry.



RN 635711-72-7 HCAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-  
3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-phenoxyphenyl)- (CA  
INDEX NAME)

Absolute stereochemistry.




RN 635711-73-8 HCAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-  
3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-naphthalenyl)- (CA  
INDEX NAME)

Absolute stereochemistry.


L17 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635711-77-2 HCAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-  
3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-methylphenyl)- (CA  
INDEX NAME)

Absolute stereochemistry.




RN 635711-78-3 HCAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-  
3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-ethylphenyl)- (CA  
INDEX NAME)

Absolute stereochemistry.


L17 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635711-75-0 HCAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-  
3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4,5-trimethylphenyl)- (CA  
INDEX NAME)

Absolute stereochemistry.




RN 635711-76-1 HCAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-  
3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chlorophenyl)- (CA  
INDEX NAME)

Absolute stereochemistry.


L17 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635711-79-4 HCAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-  
3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-phenyl- (CA INDEX  
NAME)


Absolute stereochemistry.



RN 635711-80-7 HCAPLUS

CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-  
quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-phenyl- (CA INDEX NAME)

Absolute stereochemistry.




L17 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)

RN 635711-82-9 HCAPLUS

CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(4-phenoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-83-0 HCAPLUS

CN Urea, N-(3-acetylphenyl)-N'-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-84-1 HCAPLUS

CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(2,3-dichlorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.


L17 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635711-88-5 HCAPLUS

CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(2,3-dimethylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-89-6 HCAPLUS

CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(4-chloro-3-(trifluoromethyl)phenyl)- (CA INDEX NAME)

Absolute stereochemistry.


L17 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635711-86-3 HCAPLUS

CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(2-methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-87-4 HCAPLUS

CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(3-methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.


L17 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635711-90-9 HCAPLUS

CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(3-chloro-4-(trifluoromethyl)phenyl)- (CA INDEX NAME)


Absolute stereochemistry.




RN 635711-91-0 HCAPLUS

CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(1R,2S)-2-phenylcyclopropyl)- (CA INDEX NAME)


Absolute stereochemistry.




Absolute stereochemistry.




Absolute stereochemistry.




Absolute stereochemistry.




Absolute stereochemistry.




Absolute stereochemistry.




Absolute stereochemistry.




Absolute stereochemistry.




Absolute stereochemistry.




Absolute stereochemistry.




Absolute stereochemistry.




Absolute stereochemistry.




Absolute stereochemistry.




Absolute stereochemistry.



Absolute stereochemistry.




Absolute stereochemistry.




Absolute stereochemistry.

L17 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RN 635712-11-7 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(2,5-dimethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-12-8 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(2-ethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RN 635712-13-9 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(3-bromophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-14-0 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(3-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RN 635712-15-1 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(3-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-16-2 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(4-bromophenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RN 635712-17-3 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(4-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-19-5 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(4-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)



RN 635712-20-8 HCAPLUS  
 CN Benzoic acid, 4-[[[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]amino]carbonylamino]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-22-0 HCAPLUS  
 CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-difluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)



RN 635712-23-1 HCAPLUS  
 CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-24-2 HCAPLUS  
 CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-4-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)



RN 635712-25-3 HCAPLUS  
 CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(5-chloro-2-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-26-4 HCAPLUS  
 CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chloro-2-(trifluoromethyl)phenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)




RN 635712-27-5 HCAPLUS  
 CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-ethoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-28-6 HCAPLUS  
 CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-ethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.




Absolute stereochemistry.





Absolute stereochemistry.




Absolute stereochemistry.





Absolute stereochemistry.




Absolute stereochemistry.



Absolute stereochemistry.




Absolute stereochemistry.



Absolute stereochemistry.


L17 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN  
AN 2005:564638 HCAPLUS  
DN 143:97382  
TI Preparation of urea derivatives as activated blood coagulation factor X (FXa) inhibitors  
IN Kubo, Keiji; Inaeda, Yasuhiro  
PA Takeda Pharmaceutical Company Limited, Japan  
SO PCT Int. Appl., 236 pp.  
CODEN: PFXK32  
DT Patent  
LA Japanese  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO-2005058223	A1	20050630	2004WO-JP018717	20041215
W: AE, AC, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CB, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
FW: BW, GH, GM, GR, KE, LS, MW, ME, NA, SD, SL, SE, SZ, UG, ZM, ZW, AM, AE, BY, KG, KZ, MD, RU, TJ, TM, AZ, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, SN, TD, TG				
CA-----2550012	A1	20050630	2004CA-002550012	20041215
EP-----1695961	A1	20060830	2004EP-000807076	20041215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
US-20070093501	A1	20070426	2006US-000583046	20060615
PRAI 2003JP-00420031	A	20031217		
2004WO-JP018717	W	20041215		
OS MAPPAT 143:97382				
GI				




AB The title compds. I (Cy represents an optionally substituted aromatic hydrocarbon group or optionally substituted aromatic heterocyclic group; R1 represents hydrogen or an optionally substituted hydrocarbon group; V represents C(O), S(O), or S(O)2; W represents N(R2), O, or a bond (R2 represents hydrogen or an optionally substituted hydrocarbon group); X represents optionally substituted alkylene; Y represents C(O), S(O), or S(O)2; Z represents a bond, an optionally substituted chain hydrocarbon group, etc.; ring A represents an optionally substituted nonarom. nitrogenous heterocycle; ring B represents an optionally substituted nitrogenous heterocycle; and the dotted line indicates a single bond or double bond; provided that R1 may be bonded to R2 to form an optionally substituted nonarom. nitrogenous heterocycle and that R2 may be bonded to a substituent of X to form an optionally substituted nonarom. nitrogenous heterocycle) are prepared. Thus, N-(4-chlorophenyl)-N'-((1R)-2,2-dimethyl-1-((3-(3-oxo-1H-imidazo[1,5-a]imidazol-2(3H)-yl)-1-pyrrolidinyl)carbonyl)propyl)urea was prepared in several steps from 1-benzyl-5-pyrrolidinemine and imidazole-2-carbaldehyde. Compds. of this invention in vitro showed IC50 values of 10 nM to 50 nM against FXa. Formulations are given.

II RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
[preparation of urea derivs. as activated blood coagulation factor X inhibitors]  
RN 856416-69-8 HCAPLUS  
CN Urea, N-(4-chlorophenyl)-N'-((1R)-2,2-dimethyl-1-((2-oxo[1,4'-bipiperidin]-

L17 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
1'-(yl)carbonylpropyl)- (CA INDEX NAME)



Absolute stereochemistry.



RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN  
AN 2004:857166 HCAPLUS  
DN 141:332218  
TI Preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists  
IN Chaturvedula, Prasad V.; Chen, Ling; Civiello, Rita; Conway, Charles Mark; Degnan, Andrew P.; Dubowchik, Gene M.; Han, Xiaojun; Jiang, Xiang Jun; Karageorge, George N.; Luo, Guanglin; Macor, John E.; Poindexter, Graham; Tora, George; Vig, Shikha  
PA Bristol-Myers Squibb Company, USA  
SO U.S. Pat. Appl. Publ., 203 pp., Cont.-in-part of U.S. Ser. No. 445,523.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US-20040204397	A1	20041014	2003US-000729155	20031205
US-----7220862	B2	20070522		
US-20040063735	A1	20040401	2003US-000445523	20030527
ZA-2004009634	A	20060726	2004ZA-00009634	20041129
US-20070148093	A1	20070628	2006US-000641974	20061219
US-20070149502	A1	20070628	2007US-000620253	20070105
US-20070149503	A1	20070628	2007US-000620206	20070105
US-20070232600	A1	20071004	2007US-000620291	20070105
US-----7314883	B2	20080101		
2002US-00386138P	P	20020605		
2002US-0038617P	P	20020613		
2002US-00389870P	P	20020619		
2002US-00393200P	P	20020701		
2002US-00413534P	P	20020925		
2003US-000445523	A2	20030527		
2003US-000729155	A3	20031205		
OS MAPPAT 141:332218				
GI				



AB Diazaheterocycles I [m, n = 0-2; V = (un)substituted NH2, OH; Q = (un)substituted alkyl, NH2, NHC(=O)H, NHC(=O)NH2; U = CH2, NH; D = O, NCN, alkylsulfonylimino; A = C, N, CH; E = (un)substituted heterocyclic; with proviso] were prepared for use as antagonists of calcitonin gene-related peptide receptors for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). Thus, the indazole II was prepared from 1H-indazole-5-carboxaldehyde and had IC50 for calcitonin gene related peptide receptor binding of  $\leq 10$  nM. The pharmaceutical composition comprising the compound I is claimed.  
II 635711-71-6P 635711-72-7P 635711-73-8P 635711-75-0P 635711-76-1P 635711-77-2P 635711-78-3P 635711-79-4P 635711-80-7P

L17 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)

635711-82-3P 635711-83-0P 635711-84-1P  
 635711-86-3P 635711-87-4P 635711-88-5P  
 635711-89-6P 635711-90-9P 635711-91-0P  
 635711-92-1P 635711-93-2P 635711-94-3P  
 635711-95-4P 635711-96-5P 635711-97-6P  
 635711-98-7P 635711-99-8P 635712-00-4P  
 635712-01-5P 635712-02-6P 635712-04-8P  
 635712-05-9P 635712-08-2P 635712-09-3P  
 635712-10-6P 635712-11-7P 635712-12-6P  
 635712-13-9P 635712-14-0P 635712-15-1P  
 635712-16-2P 635712-17-3P 635712-19-5P  
 635712-20-8P 635712-22-0P 635712-23-1P  
 635712-24-2P 635712-25-3P 635712-26-4P  
 635712-27-5P 635712-28-6P 635712-29-7P  
 635712-30-0P 635712-31-1P 635712-32-2P  
 635712-33-3P 635712-34-4P 635712-35-5P  
 635712-38-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of diastereocycles as calcitonin gene related peptide receptor antagonists)

RN 635711-71-6 HCAPLUS

CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-2-naphthalenyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-72-7 HCAPLUS

CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(2-phenoxyphe- (CA INDEX NAME)

Absolute stereochemistry.


L17 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RN 635711-73-8 HCAPLUS

CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-1-naphthalenyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-75-0 HCAPLUS

CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(2,4,5-trimethylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.


L17 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RN 635711-76-1 HCAPLUS

CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(4-chlorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-77-2 HCAPLUS

CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(2-methylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.


L17 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RN 635711-78-3 HCAPLUS

CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(3-ethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-79-4 HCAPLUS

CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-phenyl- (CA INDEX NAME)

Absolute stereochemistry.




L17 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)

RN 635711-80-7 HCAPLUS

CN Urea, N-([1S]-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-phenoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-82-9 HCAPLUS

CN Urea, N-([1S]-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-phenoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-83-0 HCAPLUS

CN Urea, N-(3-acetylphenyl)-N'-([1S]-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)- (CA INDEX NAME)

Absolute stereochemistry.


L17 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635711-87-4 HCAPLUS

CN Urea, N-([1S]-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-88-5 HCAPLUS

CN Urea, N-([1S]-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3-dimethylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.


L17 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635711-84-1 HCAPLUS

CN Urea, N-([1S]-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3-dichlorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-86-3 HCAPLUS

CN Urea, N-([1S]-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.


L17 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635711-89-6 HCAPLUS

CN Urea, N-([1S]-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chloro-3-(trifluoromethyl)phenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-90-9 HCAPLUS

CN Urea, N-([1S]-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-(trifluoromethyl)phenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)



RN 635711-91-0 HCAPLUS  
CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(1R,2S)-2-phenylcyclopropyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-92-1 HCAPLUS  
CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(2,4-dimethoxyphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)



RN 635711-93-2 HCAPLUS  
CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(2,4-difluorophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-94-3 HCAPLUS  
CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(2,5-dimethylphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)



RN 635711-95-4 HCAPLUS  
CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(3,4-dimethylphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-96-5 HCAPLUS  
CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(3,5-dichlorophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)



RN 635711-97-6 HCAPLUS  
CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(4-(trifluoromethyl)phenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-98-7 HCAPLUS  
CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(2,4-dichlorophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635711-99-8 HCAPLUS  
 CN Urea, N-([(1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(4-(1-methylethyl)phenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-00-4 HCAPLUS  
 CN Urea, N-([(1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(2,6-difluorophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635712-01-5 HCAPLUS  
 CN Urea, N-([(1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(2,6-dichloro-4-pyridinyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-02-6 HCAPLUS  
 CN Urea, N-([(1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(3,5-dimethoxyphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635712-04-8 HCAPLUS  
 CN Urea, N-([(1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(2-chloro-5-(trifluoromethyl)phenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-05-9 HCAPLUS  
 CN Urea, N-([(1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(2,3,4-trifluorophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635712-08-2 HCAPLUS  
 CN Urea, N-([(1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(2-fluorophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-09-3 HCAPLUS  
 CN Urea, N-([(1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-[(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(2-chlorophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)



RN 635712-10-6 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(2,5-dichlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-11-7 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(2,5-dimethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)



RN 635712-12-8 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(2-ethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-13-9 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(3-bromophenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)



RN 635712-14-0 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(3-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-15-1 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(3-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)



RN 635712-16-2 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(4-bromophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-17-3 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(4-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635712-19-5 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(4-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-20-8 HCAPLUS  
 CN Benzoic acid, 4-[[[[(1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl]amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635712-22-0 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(2,5-difluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-23-1 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(2,4-dimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635712-24-2 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(3-chloro-4-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-25-3 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(5-chloro-2-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635712-26-4 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(4-chloro-2-(trifluoromethyl)phenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-27-5 HCAPLUS  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-(4-ethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)



RN 635712-28-6 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-ethylphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-29-7 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chloro-2-methylphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)



RN 635712-30-0 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-2-methylphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-31-1 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-4-fluorophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)



RN 635712-32-2 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-bromo-2-methylphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-33-3 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(5-fluoro-2-methylphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)



RN 635712-34-4 HCAPLUS  
 CN Benzoic acid, 3-[[[(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]amino]carbonyl]methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-35-5 HCAPLUS  
 CN Urea, N-([1,1'-biphenyl]-2-yl-N'-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RN 635712-38-8 HCAPLUS  
 CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 119 THERE ARE 119 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON STN

AN 2003:891516 HCAPLUS  
 DN 140:42208  
 TI Preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists  
 IN Chaturvedula, Prasad V.; Chen, Ling; Civiello, Rita; Conway, Charles Mark; Degnan, Andrew P.; Dubowchik, Gene M.; Han, Xiaojun; Karageorge, George N.; Luo, Guanglin; Macor, John E.; Poindexter, Graham; Vig, Shikha  
 PA Bristol-Myers Squibb Company, USA  
 SO PCT Int. Appl., 309 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2003104236	A1	20031218	2003WO-US0016576	20030527
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BE, CA, CH, CN, CO, CR, CU, CE, DE, DK, DM, DS, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TE, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
FW:	GH, GM, KE, LS, MW, ME, SD, SE, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, NL, NL, PT, RO, SE, SI, SK, TA, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA----	2487976	A1	20031218	2003CA-002487976
AU--2003237255	A1	20031222	2003AU-000237255	20030527
BR--2003011812	A	20030329	2003BR-000011812	20030527
EP-----	1539766	A1	20050615	2003EP-000736721
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN-----	1671711	A	20050921	2003CN-000818475
JP--2005538959	T	20051222	2004JP-000511306	20030527
NE-----	537315	A	20060428	2003NE-000537315
NO--2004005219	A	20050228	2004NO-00005219	20041129
ZA--2004009654	A	20060726	2004ZA-000009654	20041129
MX--2004PA11960	A	20050331	2004MX-PA0011960	20041130
IN--2004DN03814	A	20070427	2004IN-DN0003814	20041130
PRAI 2002US-0386138P	P	20020605		
2002US-0388617P	P	20020613		
2002US-0389670P	P	20020619		
2002US-0393200P	P	20020701		
2002US-00413934P	P	20020925		
2003WO-US0016576	W	20030527		
OS MARPAT 140:42208				

L17 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



AB Diazaheterocycles I [m, n = 0-2; m = n = 2; V = (un)substituted NH<sub>2</sub>, OH, Q = (un)substituted alkyl, NH<sub>2</sub>, NHC(=O)H, NHC(=O)NH<sub>2</sub>; U = CH<sub>2</sub>, NH; D = O, NCH<sub>3</sub>, alkylsulfonylimino; A = C, N, CH; E = (un)substituted heterocyclic] were prepared for use as antagonists of calcitonin gene-related peptide receptors for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). Thus, the indazole II was prepared from 1H-indazole-5-carboxaldehyde and had IC<sub>50</sub> for calcitonin gene related peptide receptor binding of  $\leq 10$  nM.


IT 635711-71-6P 635711-72-7P 635711-75-8P  
 635711-75-0P 635711-76-1P 635711-77-2P  
 635711-78-3P 635711-79-4P 635711-80-7P  
 635711-82-9P 635711-83-0P 635711-84-1P  
 635711-86-3P 635711-87-4P 635711-88-5P  
 635711-89-6P 635711-90-9P 635711-91-0P  
 635711-92-1P 635711-93-2P 635711-94-3P  
 635711-95-4P 635711-96-5P 635711-97-6P  
 635711-98-7P 635711-99-8P 635712-00-4P  
 635712-01-5P 635712-02-6P 635712-04-8P  
 635712-05-9P 635712-08-2P 635712-09-3P  
 635712-10-6P 635712-11-7P 635712-12-8P  
 635712-13-9P 635712-14-0P 635712-15-1P  
 635712-16-2P 635712-17-3P 635712-19-5P  
 635712-20-8P 635712-22-0P 635712-23-1P  
 635712-24-2P 635712-25-3P 635712-26-4P  
 635712-27-5P 635712-28-6P 635712-29-7P  
 635712-30-0P 635712-31-1P 635712-32-2P  
 635712-33-3P 635712-34-4P 635712-35-5P  
 635712-38-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists)

RN 635711-71-6 HCAPLUS  
 CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-2-naphthalenyl]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RN 635711-72-7 HCAPLUS  
 CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-2-(2-phenoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-73-8 HCAPLUS  
 CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-2-naphthalenyl]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635711-75-0 HCAPLUS  
 CN Urea, N-([1S]-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(2,4,5-trimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-76-1 HCAPLUS  
 CN Urea, N-([1S]-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(4-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635711-77-2 HCAPLUS  
 CN Urea, N-([1S]-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(2-methylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-78-3 HCAPLUS  
 CN Urea, N-([1S]-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(3-ethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 635711-79-4 HCAPLUS  
 CN Urea, N-([1S]-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-phenyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-80-7 HCAPLUS  
 CN Urea, N-([1S]-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(4-phenoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




L17 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635711-83-0 HCAPLUS  
 CN Urea, N-([1S]-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(4-phenoxypheyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-84-1 HCAPLUS  
 CN Urea, N-([1S]-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(2,4-dichlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635711-86-3 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-methoxyphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-87-4 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-methoxyphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635711-88-5 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3-dimethylphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-89-6 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chloro-3-(trifluoromethyl)phenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635711-90-9 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dimethoxyphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-91-0 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-difluorophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 635711-92-1 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dimethoxyphenyl)]- (CA INDEX NAME)

Absolute stereochemistry.



RN 635711-93-2 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-difluorophenyl)]- (CA INDEX NAME)

Absolute stereochemistry.




L17 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 635711-94-3 HCAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dimethylphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635711-95-4 HCAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,4-dimethylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-96-5 HCAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,5-dichlorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.


L17 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 635711-99-8 HCAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dichlorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-00-4 HCAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,5-difluorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.


L17 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 635711-97-6 HCAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-(trifluoromethyl)phenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-98-7 HCAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,4-dichlorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.


L17 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 635712-01-5 HCAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,6-dichloro-4-pyridinyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-02-6 HCAPLUS

CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3,5-dimethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 635712-04-8 HCAPLUS  
 CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-chloro-5-(trifluoromethyl)phenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-05-9 HCAPLUS  
 CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,3,4-trifluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 635712-08-2 HCAPLUS  
 CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-09-3 HCAPLUS  
 CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-chlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 635712-10-6 HCAPLUS  
 CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dichlorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-11-7 HCAPLUS  
 CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2,5-dimethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 635712-12-8 HCAPLUS  
 CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(2-ethoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-13-9 HCAPLUS  
 CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-bromophenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635712-14-0 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(3-fluorophenyl)]- (CA INDEX NAME)]


Absolute stereochemistry.



RN 635712-15-1 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(3-chlorophenyl)]- (CA INDEX NAME)]


Absolute stereochemistry.

L17 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635712-16-2 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(4-bromophenyl)]- (CA INDEX NAME)]


Absolute stereochemistry.



RN 635712-17-3 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(4-fluorophenyl)]- (CA INDEX NAME)]


Absolute stereochemistry.

L17 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635712-19-5 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(4-methoxyphenyl)]- (CA INDEX NAME)]


Absolute stereochemistry.



RN 635712-20-8 HCAPLUS  
 CN Benzoic acid, 4-[[[(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)]


Absolute stereochemistry.

L17 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 635712-22-0 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(2,5-difluorophenyl)]- (CA INDEX NAME)]


Absolute stereochemistry.



RN 635712-23-1 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl)-N'-(2,4-dimethylphenyl)]- (CA INDEX NAME)]


Absolute stereochemistry.

L17 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)



RN 635712-24-2 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-4-methylphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-25-3 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(5-chloro-2-methoxyphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)



RN 635712-26-4 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-chloro-2-(trifluoromethyl)phenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-27-5 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-ethoxyphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)



RN 635712-28-6 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(4-ethylphenyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-29-7 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-2-fluorophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.

L17 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)




RN 635712-30-0 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-4-methylphenyl)]- (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-31-1 HCAPLUS  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-(3-chloro-4-fluorophenyl)]- (CA INDEX NAME)


Absolute stereochemistry.




Absolute stereochemistry.




Absolute stereochemistry.




Absolute stereochemistry.



Absolute stereochemistry.



Absolute stereochemistry.




```
=> b uspatall
FILE 'USPATFULL' ENTERED AT 14:15:09 ON 06 MAY 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 14:15:09 ON 06 MAY 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:15:09 ON 06 MAY 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitrn fhitstr 120 tot
```

L20 ANSWER 1 OF 1 USPATFULL on STN  
 AN 2006189981 USPATFULL  
 TI Ureas as factor Xa inhibitors  
 IN Song, Yonghong, Foster City, CA, UNITED STATES  
 Zhu, Bing-tan, Palo Alto, CA, UNITED STATES  
 Wang, Shumei, Foster City, CA, UNITED STATES  
 Bhakta, Chhaya, Hayward, CA, UNITED STATES  
 PA Scarborough, Robert M., Half Moon Bay, CA, UNITED STATES  
 Portola Pharmaceuticals, Inc., South San Francisco, CA, UNITED STATES  
 (U.S. corporation)  
 PI US-20060160821 A1 20060720  
 AI 2005US-000292317 A1 20051207 (11)  
 PRAI 2004US-000634201P 20041207 (60)  
 DT Utility  
 FS APPLICATION  
 LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH  
 FLOOR, SAN FRANCISCO, CA, 94111-3834, US  
 CLMN Number of Claims: 38  
 ECL Exemplary Claim: 1  
 DRWN 23 Drawing Page(s)  
 LN.CNT 4916  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The present invention is directed to compounds represented by Formula I  
 and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs  
 thereof which are inhibitors of Factor Xa. The present invention is also  
 directed to and intermediates used in making such compounds,  
 pharmaceutical compositions containing such compounds, methods to  
 prevent or treat a number of conditions characterized by undesired  
 thrombosis and methods of inhibiting the coagulation of a blood sample.  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 IT 855524-53-7P  
 (preparation of amino acid urea derivs. as factor Xa inhibitors)  
 IT 855524-53-7P  
 (preparation of amino acid urea derivs. as factor Xa inhibitors)  
 RN 855524-53-7 USPATFULL  
 CN Urea, N-(4-chlorophenyl)-N'-((1R)-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-  
 oxo-1-phenylethyl)- (CA INDEX NAME)  
 Absolute stereochemistry.



=> d bib abs hitrn fhitstr l21 tot


L21 ANSWER 1 OF 11 USPATFULL on STN  
 AN 2007:16523 USPATFULL  
 TI ANTI-MIGRAINE TREATMENTS  
 IN Chen, Ling, Middletown, CT, UNITED STATES  
 Chaturvedula, Prasad V., Cheshire, CT, UNITED STATES  
 Civilello, Rita, Killingworth, CT, UNITED STATES  
 Degnan, Andrew P., Rocky Hill, CT, UNITED STATES  
 Dubowchik, Gene M., Middlefield, CT, UNITED STATES  
 Han, Xiaojun, Cheshire, CT, UNITED STATES  
 Jiang, Xiang Jun J., North Haven, CT, UNITED STATES  
 Karageorge, George N., Portland, CT, UNITED STATES  
 Luo, Guanglin, Madison, CT, UNITED STATES  
 Macor, John E., Guilford, CT, UNITED STATES  
 Poindexter, Graham S., Old Saybrook, CT, UNITED STATES  
 Tora, George O., Meriden, CT, UNITED STATES  
 Bristol-Myers Squibb Company (U.S. corporation)  
 PA US-20070232600 A1 20071004  
 PI US-20070232600 B2 20080101  
 AI 2007US-000620291 A1 20070105 (11)  
 RLI Continuation-in-part of Ser. No. 2003US-000729155, filed on 5 Dec 2003,  
 GRANTED, Pat. No. US-7220862  
 DT Utility  
 FS APPLICATION  
 LREP LOUIS J. WILLE, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX  
 4000, PRINCETON, NJ, 08543-4000, US  
 CLAIM Number of Claims: 36  
 ECL Exemplary Claim: 1  
 DRWN 5 Drawing Page(s)  
 LN CNT 9251  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods of treating neurogenic  
 vasodilation, neurogenic inflammation, migraine and other headaches,  
 thermal injury, circulatory shock, flushing associated with menopause,  
 airway inflammatory diseases, such as asthma and chronic obstructive  
 pulmonary disease (COPD), and other conditions the treatment of which  
 can be effected by the antagonism of CGRP-receptors using pharmaceutical  
 compositions comprising compounds of Formula (I) ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 635711-71-6P 635711-72-7P 635711-73-8P  
 635711-75-0P 635711-76-1P 635711-77-2P  
 635711-78-3P 635711-79-4P 635711-80-7P  
 635711-82-9P 635711-83-0P 635711-84-1P  
 635711-86-3P 635711-87-4P 635711-88-5P  
 635711-89-6P 635711-90-9P 635711-91-0P  
 635711-92-1P 635711-93-2P 635711-94-3P  
 635711-95-4P 635711-96-5P 635711-97-6P  
 635711-98-7P 635711-99-8P 635712-00-4P  
 635712-01-5P 635712-02-6P 635712-04-8P  
 635712-05-9P 635712-08-2P 635712-09-3P  
 635712-10-6P 635712-11-7P 635712-12-8P  
 635712-13-9P 635712-14-0P 635712-15-1P  
 635712-16-2P 635712-17-3P 635712-19-5P  
 635712-20-8P 635712-22-0P 635712-23-1P  
 635712-24-2P 635712-25-3P 635712-26-4P  
 635712-27-5P 635712-28-6P 635712-29-7P  
 635712-30-0P 635712-31-1P 635712-32-2P  
 635712-33-3P 635712-34-4P 635712-35-5P  
 635712-38-8P  
 (preparation of diastereocycles as calcitonin gene related peptide  
 receptor antagonists for treating migraine and other diseases)  
 IT 635711-71-6P  
 (preparation of diastereocycles as calcitonin gene related peptide  
 receptor antagonists for treating migraine and other diseases)  
 RN 635711-71-6 USPATFULL  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin)-1'-ylcarbonyl]-3-[4-(1,4-dihydro-2-oxo-  
 3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-2-naphthalenyl)- (CA  
 INDEX NAME)  
 Absolute stereochemistry.

L21 ANSWER 1 OF 11 USPATFULL on STN (Continued)




L21 ANSWER 2 OF 11 USPATFULL on STN  
 AN 2007:170816 USPATFULL  
 TI ANTI-MIGRAINE SPIROCYCLES  
 IN CHATURVEDULA, PRASAD V., Cheshire, CT, UNITED STATES  
 Chen, Ling, Middletown, CT, UNITED STATES  
 Civilello, Rita, Killingworth, CT, UNITED STATES  
 Degnan, Andrew P., Rocky Hill, CT, UNITED STATES  
 Dubowchik, Gene M., Middlefield, CT, UNITED STATES  
 Han, Xiaojun, Cheshire, CT, UNITED STATES  
 Jiang, Xiang Jun J., North Haven, CT, UNITED STATES  
 Macor, John E., Guilford, CT, UNITED STATES  
 Poindexter, Graham S., Old Saybrook, CT, UNITED STATES  
 Tora, George O., Meriden, CT, UNITED STATES  
 Luo, Guanglin, Madison, CT, UNITED STATES  
 Bristol-Myers Squibb Company (U.S. corporation)  
 PA US-20070149503 A1 20070628  
 AI 2007US-000620308 A1 20070105 (11)  
 RLI Continuation-in-part of Ser. No. 2003US-000729155, filed on 5 Dec 2003,  
 PENDING  
 DT Utility  
 FS APPLICATION  
 LREP LOUIS J. WILLE, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX  
 4000, PRINCETON, NJ, 08543-4000, US  
 CLAIM Number of Claims: 36  
 ECL Exemplary Claim: 1  
 DRWN 5 Drawing Page(s)  
 LN CNT 9071  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds of Formula (I) ##STR1##  
 as antagonists of calcitonin gene-related peptide receptors  
 ("CGRP-receptor"), pharmaceutical compositions comprising them, methods  
 for identifying them, methods of treatment using them and their use in  
 therapy for treatment of neurogenic vasodilation, neurogenic  
 inflammation, migraine and other headaches, thermal injury, circulatory  
 shock, flushing associated with menopause, airway inflammatory diseases,  
 such as asthma and chronic obstructive pulmonary disease (COPD), and  
 other conditions the treatment of which can be effected by the  
 antagonism of CGRP-receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 635711-71-6P 635711-72-7P 635711-73-8P  
 635711-75-0P 635711-76-1P 635711-77-2P  
 635711-78-3P 635711-79-4P 635711-80-7P  
 635711-82-9P 635711-83-0P 635711-84-1P  
 635711-86-3P 635711-87-4P 635711-88-5P  
 635711-89-6P 635711-90-9P 635711-91-0P  
 635711-92-1P 635711-93-2P 635711-94-3P  
 635711-95-4P 635711-96-5P 635711-97-6P  
 635711-98-7P 635711-99-8P 635712-00-4P  
 635712-01-5P 635712-02-6P 635712-04-8P  
 635712-05-9P 635712-08-2P 635712-09-3P  
 635712-10-6P 635712-11-7P 635712-12-8P  
 635712-13-9P 635712-14-0P 635712-15-1P  
 635712-16-2P 635712-17-3P 635712-19-5P  
 635712-20-8P 635712-22-0P 635712-23-1P  
 635712-24-2P 635712-25-3P 635712-26-4P  
 635712-27-5P 635712-28-6P 635712-29-7P  
 635712-30-0P 635712-31-1P 635712-32-2P  
 635712-33-3P 635712-34-4P 635712-35-5P  
 635712-38-8P  
 (preparation of piperidine-1-carboxamide derivs. and spirocyclic compds.  
 thereof as antagonists of calcitonin gene-related peptide receptors)  
 IT 635711-71-6P  
 (preparation of piperidine-1-carboxamide derivs. and spirocyclic compds.  
 thereof as antagonists of calcitonin gene-related peptide receptors)  
 RN 635711-71-6 USPATFULL  
 CN Urea, N-([(1S)-1-([(1,4'-bipiperidin)-1'-ylcarbonyl]-3-[4-(1,4-dihydro-2-oxo-  
 3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-2-naphthalenyl)- (CA  
 INDEX NAME)  
 Absolute stereochemistry.

L21 ANSWER 2 OF 11 USPATFULL on STN (Continued)



121 ANSWER 3 OF 11 USPATFUL on STN  
AN 2007:170815 USPATFULL  
II SPIROICLAD ANTI-MIGRAINE COMPOUNDS  
IN Chaturvedi, Prasad V., Cheshire, CT, UNITED STATES  
Dobuchnick, Gene M., Middlefield, CT, UNITED STATES  
Jiang, Xiang Jun J., North Haven, CT, UNITED STATES  
Macor, John E., Guilford, CT, UNITED STATES  
Poindexter, Graham S., Old Saybrook, CT, UNITED STATES  
Vig, Shikha, Durham, CT, UNITED STATES  
PA Bristol-Myers Squibb Company (U.S. corporation)  
DI US-20070149502 AI 20070628  
RI US-2007-006620253 AI 20070105 (11)  
PLI Division of Ser. No. 2007HE-000729155, filed on 5 Dec 2003, PENDING  
DT Utility  
FS APLICATION  
LREP LOUIS J. LEBLE, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX  
4000, PRINCETON, NJ, 08543-4000, US  
CINM Number of Claims: 33  
ECL Exemplary Claim: 1  
DWIN 5 Drawing Page(s)  
LN.CNT 8886

AS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds of Formula (I) ##STR1## as agonists of the pharmacological group related peptide receptors, in particular of the CGRP-receptors, and to pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, neurogenic pain, neurogenic asthma, neurogenic circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```

IT  6357111-71-6P 6357111-72-7P 6357111-73-6P
6357111-75-0P 6357111-76-1P 6357111-77-2P
6357111-78-3P 6357111-79-4P 6357111-80-7P
6357111-82-9P 6357111-83-0P 6357111-84-1P
6357111-86-2P 6357111-87-4P 6357111-88-5P
6357111-89-6P 6357111-90-9P 6357111-91-0P
6357111-92-1P 6357111-93-2P 6357111-94-3P
6357111-95-4P 6357111-96-5P 6357111-97-6P
6357111-98-7P 6357111-99-8P 635712-00-4P
635712-01-5P 635712-02-6P 635712-03-8P
635712-05-9P 635712-06-2P 635712-08-3P
635712-10-6P 635712-11-7P 635712-12-8P
635712-13-0P 635712-14-0P 635712-15-1P
635712-16-2P 635712-17-3P 635712-19-5P
635712-20-0P 635712-22-0P 635712-23-1P
635712-24-2P 635712-25-3P 635712-26-4P
635712-27-5P 635712-28-6P 635712-29-7P
635712-30-0P 635712-31-1P 635712-32-2P
635712-33-3P 635712-34-4P 635712-35-5P
635712-38-8P

```

(preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists)

IT 635711-71-6P  
(preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists)

Receptor antagonists)  
RN 635711-71-6 USPATFULL  
CN Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-2-naphthalenyl- (CA  
(INDEX NAME)

Absolute stereochemistry.

L21 ANSWER 4 OF 113 USPATFULL ON STN  
AN 2007:169413 USPATFULL  
N1 Non-terminal method of identifying anti-migraine compounds  
IN Conney, Charles Mark, Cheshire, CT, UNITED STATES  
PA Bristol-Myers Squibb Company (U.S. corporation)  
PI US-20070148093 Al 20070628  
AL 2006-000491974 Al 8/06/2013 (11)  
PLI Division of Ser. No. 2003US-000729155, filed on 5 Dec 2003, PENDING  
Continuation-in-part of Ser. No. 2003US-000445523, filed on 27 May 2003.  
PRAI 2002US-000386138P 20020605 (60)  
2002US-000386617P 20020613 (60)  
2002US-000389870P 20020709 (60)  
2002US-000393200P 20020701 (60)  
2002US-000413534P 20020925 (60)  
DS Utility  
FT APPLICATION  
LREP LOUIS J. WILLE, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX  
4000, PRINCETON, NJ, 08543-4000, US  
CLMN Number of Claims: 4  
ECL Exemplary Claim: 1  
DRMN 5 Drawing Page(s)  
DR CNT 8571

AB The present invention relates to in vivo non-terminal method of identifying anti-migraine compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

135  
 136  
 137  
 138  
 139  
 140  
 141  
 142  
 143  
 144  
 145  
 146  
 147  
 148  
 149  
 150  
 151  
 152  
 153  
 154  
 155  
 156  
 157  
 158  
 159  
 160  
 161  
 162  
 163  
 164  
 165  
 166  
 167  
 168  
 169  
 170  
 171  
 172  
 173  
 174  
 175  
 176  
 177  
 178  
 179  
 180  
 181  
 182  
 183  
 184  
 185  
 186  
 187  
 188  
 189  
 190  
 191  
 192  
 193  
 194  
 195  
 196  
 197  
 198  
 199  
 200  
 201  
 202  
 203  
 204  
 205  
 206  
 207  
 208  
 209  
 210  
 211  
 212  
 213  
 214  
 215  
 216  
 217  
 218  
 219  
 220  
 221  
 222  
 223  
 224  
 225  
 226  
 227  
 228  
 229  
 230  
 231  
 232  
 233  
 234  
 235  
 236  
 237  
 238  
 239  
 240  
 241  
 242  
 243  
 244  
 245  
 246  
 247  
 248  
 249  
 250  
 251  
 252  
 253  
 254  
 255  
 256  
 257  
 258  
 259  
 260  
 261  
 262  
 263  
 264  
 265  
 266  
 267  
 268  
 269  
 270  
 271  
 272  
 273  
 274  
 275  
 276  
 277  
 278  
 279  
 280  
 281  
 282  
 283  
 284  
 285  
 286  
 287  
 288  
 289  
 290  
 291  
 292  
 293  
 294  
 295  
 296  
 297  
 298  
 299  
 300  
 301  
 302  
 303  
 304  
 305  
 306  
 307  
 308  
 309  
 310  
 311  
 312  
 313  
 314  
 315  
 316  
 317  
 318  
 319  
 320  
 321  
 322  
 323  
 324  
 325  
 326  
 327  
 328  
 329  
 330  
 331  
 332  
 333  
 334  
 335  
 336  
 337  
 338  
 339  
 340  
 341  
 342  
 343  
 344  
 345  
 346  
 347  
 348  
 349  
 350  
 351  
 352  
 353  
 354  
 355  
 356  
 357  
 358  
 359  
 360  
 361  
 362  
 363  
 364  
 365  
 366  
 367  
 368  
 369  
 370  
 371  
 372  
 373  
 374  
 375  
 376  
 377  
 378  
 379  
 380  
 381  
 382  
 383  
 384  
 385  
 386  
 387  
 388  
 389  
 390  
 391  
 392  
 393  
 394  
 395  
 396  
 397  
 398  
 399  
 400  
 401  
 402  
 403  
 404  
 405  
 406  
 407  
 408  
 409  
 410  
 411  
 412  
 413  
 414  
 415  
 416  
 417  
 418  
 419  
 420  
 421  
 422  
 423  
 424  
 425  
 426  
 427  
 428  
 429  
 430  
 431  
 432  
 433  
 434  
 435  
 436  
 437  
 438  
 439  
 440  
 441  
 442  
 443  
 444  
 445  
 446  
 447  
 448  
 449  
 450  
 451  
 452  
 453  
 454  
 455  
 456  
 457  
 458  
 459  
 460  
 461  
 462  
 463  
 464  
 465  
 466  
 467  
 468  
 469  
 470  
 471  
 472  
 473  
 474  
 475  
 476  
 477  
 478  
 479  
 480  
 481  
 482  
 483  
 484  
 485  
 486  
 487  
 488  
 489  
 490  
 491  
 492  
 493  
 494  
 495  
 496  
 497  
 498  
 499  
 500  
 501  
 502  
 503  
 504  
 505  
 506  
 507  
 508  
 509  
 510  
 511  
 512  
 513  
 514  
 515  
 516  
 517  
 518  
 519  
 520  
 521  
 522  
 523  
 524  
 525  
 526  
 527  
 528  
 529  
 530  
 531  
 532  
 533  
 534  
 535  
 536  
 537  
 538  
 539  
 540  
 541  
 542  
 543  
 544  
 545  
 546  
 547  
 548  
 549  
 550  
 551  
 552  
 553  
 554  
 555  
 556  
 557  
 558  
 559  
 560  
 561  
 562  
 563  
 564  
 565  
 566  
 567  
 568  
 569  
 570  
 571  
 572  
 573  
 574  
 575  
 576  
 577  
 578  
 579  
 580  
 581  
 582  
 583  
 584  
 585  
 586  
 587  
 588  
 589  
 590  
 591  
 592  
 593  
 594  
 595  
 596  
 597  
 598  
 599  
 600  
 601  
 602  
 603  
 604  
 605  
 606  
 607  
 608  
 609  
 610  
 611  
 612  
 613  
 614  
 615  
 616  
 617  
 618  
 619  
 620  
 621  
 622  
 623  
 624  
 625  
 626  
 627  
 628  
 629  
 630  
 631  
 632  
 633  
 634  
 635  
 636  
 637  
 638  
 639  
 640  
 641  
 642  
 643  
 644  
 645  
 646

(preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists)

IT 635711-71-6P  
(preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists)


```

      receptor antagonists)
RN   635711-71-6  USPATFULL
CN   Urea, N-[(1S)-1-([1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-
      3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-2-naphthalenyl- (CA
      [INDEX NAME]


```

### Absolute stereochemistry

121 ANSWER 3 OF 11 USPATFULL on STN (Continued)



121 ANSWER 4 OF 11 USPATFULL on SIN (Continued)




L21 ANSWER 5 OF 11 USPATFULL on STN  
 AN 2007107528 USPATFULL  
 TI Urea derivative, process for producing the same, and use  
 IN Kubo, Keiji, Osaka-shi, JAPAN  
 IN Ikeda, Tetsuhiko, Osaka-shi, JAPAN  
 PA TAKEDA PHARMACEUTICAL COMPANY LIMITED, OSAKA-SHI, JAPAN, 541 0045  
 (non-U.S. corporation)  
 PI US-20070093501 A1 20070426  
 AI 2004US-000583046 A1 20041215 (10)  
 2004WO-JP0018717 20041215  
 PRAI 2003JP-000420031 20031217  
 DT Utility  
 FS APPLICATION  
 LREP HAMRE, SCHUMANN, MUELLER & LARSON, P.C., P.O. BOX 2902, MINNEAPOLIS, MN,  
 55402-0902, US  
 CLMN Number of Claims: 30  
 ECL Exemplary Claim: 1  
 DRWN No Drawings  
 LN.CNT 758  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a urea derivative or a salt thereof, which is useful as a therapeutic agent for thrombosis. The derivative is represented by Formula (I): ##STR1## wherein Cy is an aromatic hydrocarbon group which may be substituted or an aromatic heterocyclic group which may be substituted; R.sub.1 is a hydrogen atom or a hydrocarbon group which may be substituted; V is --C(O)--, --S(O)--, or --S(O).sub.2--; W is --N(R.sub.2)--, --O--, or a bond (wherein R.sub.2 is a hydrogen atom or a hydrocarbon group which may be substituted); X is a alkylene which may be substituted; Y is --C(O)--, --S(O)--, or --S(O).sub.2--; Z is a bond, a chain hydrocarbon group which may be substituted, or --N.dbd.; ring A is a non-aromatic nitrogen-containing heterocyclic ring which may be substituted; ring B is a nitrogen-containing heterocyclic ring which may be substituted; and [Chemical Formula 2] ##Custom-character-00001##  
 ##Custom-character-00002## are each independently a single bond or a double bond; provided that R.sub.1 may be bonded to R.sub.2 to form a non-aromatic nitrogen-containing heterocyclic ring and that R.sub.2 may be bonded to a substituent of X to form a non-aromatic nitrogen-containing heterocyclic ring which may be substituted.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 856416-69-EP  
 (preparation of urea derivs. as activated blood coagulation factor X inhibitors)  
 IT 856416-69-EP  
 (preparation of urea derivs. as activated blood coagulation factor X inhibitors)  
 RN 856416-69-8 USPATFULL  
 CN Urea, N-(4-(chlorophenyl)-N'-((1R)-2,2-dimethyl-1-[(2-oxo[1,4'-bipiperidin]-1'-yl)carbonyl]propyl)- (CA INDEX NAME)  
 Absolute stereochemistry.




L21 ANSWER 7 OF 11 USPATFULL on STN  
 AN 2006:189350 USPATFULL  
 TI Thioureas as factor Xa inhibitors  
 IN Song, Yonghong, Foster City, CA, UNITED STATES  
 Zhu, Bing-Yan, Palo Alto, CA, UNITED STATES  
 Bhakta, Chhaya, Hayward, CA, UNITED STATES  
 Scarborough, Robert M., Half Moon Bay, CA, UNITED STATES  
 PA Portola Pharmaceuticals, Inc., South San Francisco, CA, UNITED STATES  
 (U.S. corporation)  
 PI US-20060160790 A1 20060720  
 AI 2005US-000298296 A1 20051207 (11)  
 PRAI 2004US-000634150P 20041207 (60)  
 DT Utility  
 FS APPLICATION  
 LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH  
 FLOOR, SAN FRANCISCO, CA, 94111-3834, US  
 CLMN Number of Claims: 36  
 ECL Exemplary Claim: 1  
 DRWN 5 Drawing Page(s)  
 LN.CNT 2197  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 890524-22-EP  
 (preparation of amino acid thiourea derivs. as factor Xa inhibitors)  
 IT 890524-22-EP  
 (preparation of amino acid thiourea derivs. as factor Xa inhibitors)  
 RN 890524-22-8 USPATFULL  
 CN Thiourea, N-(4-(chlorophenyl)-N'-((1R)-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxo-1-phenylethyl)- (CA INDEX NAME)  
 Absolute stereochemistry.




L21 ANSWER 6 OF 11 USPATFULL on STN  
 AN 2006:189381 USPATFULL  
 TI Ureas as factor Xa inhibitors  
 IN Song, Yonghong, Foster City, CA, UNITED STATES  
 Zhu, Bing-Yan, Palo Alto, CA, UNITED STATES  
 Wang, Shumei, Foster City, CA, UNITED STATES  
 Bhakta, Chhaya, Hayward, CA, UNITED STATES  
 Scarborough, Robert M., Half Moon Bay, CA, UNITED STATES  
 PA Portola Pharmaceuticals, Inc., South San Francisco, CA, UNITED STATES  
 (U.S. corporation)  
 PI US-20060160821 A1 20060720  
 AI 2005US-000298217 A1 20051207 (11)  
 PRAI 2004US-000634201P 20041207 (60)  
 DT Utility  
 FS APPLICATION  
 LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH  
 FLOOR, SAN FRANCISCO, CA, 94111-3834, US  
 CLMN Number of Claims: 38  
 ECL Exemplary Claim: 1  
 DRWN 23 Drawing Page(s)  
 LN.CNT 4916  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 891789-71-2P 891789-79-UP 891789-80-3P  
 (preparation of amino acid urea derivs. as factor Xa inhibitors)  
 IT 891789-71-2P  
 (preparation of amino acid urea derivs. as factor Xa inhibitors)  
 RN 891789-71-2 USPATFULL  
 CN Urea, N-(4-(chlorophenyl)-N'-((1R)-2-oxo-2-(2-oxo[1,4'-bipiperidin]-1'-yl)-1-phenylethyl)- (CA INDEX NAME)  
 Absolute stereochemistry.



L21 ANSWER 8 OF 11 USPATFULL on STN  
 AN 2004:261895 USPATFULL  
 TI Calcitonin gene related peptide receptor antagonists  
 IN Chaturvedi, Prasad V., Cheshire, CT, UNITED STATES  
 Chen, Ling, Middletown, CT, UNITED STATES  
 Civilello, Rita, Killingworth, CT, UNITED STATES  
 Conway, Charles Mark, Cheshire, CT, UNITED STATES  
 Degnan, Andrew P., New Haven, CT, UNITED STATES  
 Dubowchik, Gene M., Middlefield, CT, UNITED STATES  
 Han, Xiaojun, Cheshire, CT, UNITED STATES  
 J. Jiang, Xiang Jun, Hamden, CT, UNITED STATES  
 Karageorge, George N., Portland, CT, UNITED STATES  
 Luo, Guanglin, Madison, CT, UNITED STATES  
 Macor, John E., Guilford, CT, UNITED STATES  
 Poindexter, Graham, Old Saybrook, CT, UNITED STATES  
 Tora, George, Meriden, CT, UNITED STATES  
 Vig, Shikha, Durham, CT, UNITED STATES  
 PI US-20040204397 A1 20041014  
 US-----7220862 B2 20070522  
 AI 2003US-000729155 A1 20031205 (10)  
 RLI Continuation-in-part of Ser. No. 2003US-000445523, filed on 27 May 2003, PENDING

PRAI 2002US-00038613P 20020605 (60)  
 2002US-00038661P 20020613 (60)  
 2002US-000389870P 20020619 (60)  
 2002US-000393200P 20020701 (60)  
 2002US-000413534P 20020925 (60)  
 DT Utility  
 FS APPLICATION

LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000  
 CLMN Number of Claims: 46  
 ECL Exemplary Claim: 1  
 DRWN 5 Drawing Page(s)  
 LN.CNT 969  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds of Formula (I) ##STR1##


as antagonists of calcitonin gene-related peptide receptors ("CGRP-receptor"), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 635711-71-6P 635711-72-7P 635711-73-8P  
 635711-75-0P 635711-76-1P 635711-77-2P  
 635711-78-3P 635711-79-4P 635711-80-7P  
 635711-82-9P 635711-83-0P 635711-84-1P  
 635711-86-3P 635711-87-4P 635711-88-5P  
 635711-89-6P 635711-90-9P 635711-91-0P  
 635711-92-1P 635711-93-2P 635711-94-3P  
 635711-95-4P 635711-96-5P 635711-97-6P  
 635711-98-7P 635711-99-8P 635712-00-4P  
 635712-01-5P 635712-02-6P 635712-04-8P  
 635712-05-9P 635712-06-2P 635712-09-3P  
 635712-10-6P 635712-11-7P 635712-12-8P  
 635712-13-9P 635712-14-0P 635712-15-1P  
 635712-16-2P 635712-17-3P 635712-19-5P  
 635712-20-8P 635712-22-0P 635712-23-1P  
 635712-24-2P 635712-25-3P 635712-26-4P  
 635712-27-5P 635712-28-6P 635712-29-7P  
 635712-30-0P 635712-31-1P 635712-32-2P  
 635712-33-3P 635712-34-4P 635712-35-5P  
 635712-36-6P  
 (preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists)  
 IT 635711-71-6P  
 (preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists)  
 RN 635711-71-6 USPATFULL

L21 ANSWER 8 OF 11 USPATFULL on STN (Continued)  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-2-naphthalenyl- (CA INDEX NAME)

Absolute stereochemistry.




L21 ANSWER 9 OF 11 USPATFULL on STN  
 AN 2004:83279 USPATFULL  
 TI Calcitonin gene related peptide receptor antagonists  
 IN Chaturvedula, Prasad V., Cheshire, CT, UNITED STATES  
 Chen, Ling, Middletown, CT, UNITED STATES  
 Civilello, Rita, Killingworth, CT, UNITED STATES  
 Conway, Charles Mark, Cheshire, CT, UNITED STATES  
 Degnan, Andrew P., New Haven, CT, UNITED STATES  
 Dubowchik, Gene M., Middlefield, CT, UNITED STATES  
 Han, Xiaojun, Cheshire, CT, UNITED STATES  
 Karageorge, George N., Portland, CT, UNITED STATES  
 Luo, Guanglin, Madison, CT, UNITED STATES  
 Macor, John E., Guilford, CT, UNITED STATES  
 Poindexter, Graham, Old Saybrook, CT, UNITED STATES  
 Vlg, Shikha, Durham, CT, UNITED STATES  
 PI US-20040063735 A1 20040401  
 AI 2003US-000445523 A1 20030527 (10)  
 PRAI 2002US-000386138P 20020605 (60)  
 2002US-000386617P 20020613 (60)  
 2002US-000389870P 20020619 (60)  
 2002US-000393200P 20020701 (60)  
 2002US-000413534P 20020925 (60)  
 DT Utility  
 FS APPLICATION  
 LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000  
 CLMN Number of Claims: 38  
 ECL Exemplary Claim: 1  
 DPMN 5 Drawing Page(s)  
 LN.CNT 6913  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The present invention relates to compounds of Formula (I) ##STR1##

as antagonists of calcitonin gene-related peptide receptors ("CGRP-receptor"), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 IT 635711-71-6P 635711-72-7P 635711-73-8P  
 635711-75-0P 635711-76-1P 635711-77-2P  
 635711-78-3P 635711-79-4P 635711-80-7P  
 635711-82-9P 635711-83-0P 635711-84-1P  
 635711-86-3P 635711-87-4P 635711-88-5P  
 635711-89-6P 635711-90-9P 635711-91-0P  
 635711-92-1P 635711-93-2P 635711-94-3P  
 635711-95-4P 635711-96-5P 635711-97-6P  
 635711-98-7P 635711-99-8P 635712-00-4P  
 635712-01-5P 635712-02-6P 635712-04-8P  
 635712-05-9P 635712-08-2P 635712-09-3P  
 635712-10-6P 635712-11-7P 635712-12-8P  
 635712-13-9P 635712-14-0P 635712-15-1P  
 635712-16-2P 635712-17-3P 635712-19-5P  
 635712-20-8P 635712-22-0P 635712-23-1P  
 635712-24-2P 635712-25-3P 635712-26-4P  
 635712-27-5P 635712-28-6P 635712-29-7P  
 635712-30-0P 635712-31-1P 635712-32-2P  
 635712-33-3P 635712-34-4P 635712-35-5P  
 635712-38-8P  
 (preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists)  
 IT 635711-71-6P  
 (preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists)  
 PN 635711-71-6 USPATFULL  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-(4-(1,4-dihydro-2-oxo-

L21 ANSWER 9 OF 11 USPATFULL on STN (Continued)  
 3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-2-naphthalenyl- (CA INDEX NAME)

Absolute stereochemistry.




L21 ANSWER 10 OF 11 USPAT2 on STN  
 AN 2007:265523 USPAT2  
 TI Anti-migraine treatments  
 IN Chaturvedula, Prasad V., Cheshire, CT, UNITED STATES  
 Chen, Ling, Middletown, CT, UNITED STATES  
 Civilello, Rita, Killingworth, CT, UNITED STATES  
 Degnan, Andrew P., Rocky Hill, CT, UNITED STATES  
 Dubowchik, Gene M., Middlefield, CT, UNITED STATES  
 Han, Xiaojun, Cheshire, CT, UNITED STATES  
 Jiang, Xiang Jun J., North Haven, CT, UNITED STATES  
 Karageorge, George N., Portland, CT, UNITED STATES  
 Luo, Guanglin, Madison, CT, UNITED STATES  
 Macor, John E., Guilford, CT, UNITED STATES  
 Poindexter, Graham S., Old Saybrook, CT, UNITED STATES  
 Tora, George O., Meriden, CT, UNITED STATES  
 PA Bristol-Myers Squibb Company, Princeton, NJ, UNITED STATES (U.S. corporation)  
 PI US-200714883 B2 20080101  
 AI 2007US-000620291 20070105 (11)  
 LRI Continuation-in-part of Ser. No. 2003US-000729155, filed on 5 Dec 2003,  
 Pat. No. US-200720862  
 DT Utility  
 FS GRANTED  
 EXNAM Primary Examiner: Balasubramanian, Venkataraman  
 LREP Makujina, Shah R.  
 CLMN Number of Claims: 36  
 ECL Exemplary Claim: 1  
 DPMN 5 Drawing Figure(s); 5 Drawing Page(s)  
 LN.CNT 9260  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The present invention relates to methods of treating neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors using pharmaceutical compositions comprising compounds of Formula (I)

##STR1##  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 IT 635711-71-6P 635711-72-7P 635711-73-8P  
 635711-75-0P 635711-76-1P 635711-77-2P  
 635711-78-3P 635711-79-4P 635711-80-7P  
 635711-82-9P 635711-83-0P 635711-84-1P  
 635711-86-3P 635711-87-4P 635711-88-5P  
 635711-89-6P 635711-90-9P 635711-91-0P  
 635711-92-1P 635711-93-2P 635711-94-3P  
 635711-95-4P 635711-96-5P 635711-97-6P  
 635711-98-7P 635711-99-8P 635712-00-4P  
 635712-01-5P 635712-02-6P 635712-04-8P  
 635712-05-9P 635712-08-2P 635712-09-3P  
 635712-10-6P 635712-11-7P 635712-12-8P  
 635712-13-9P 635712-14-0P 635712-15-1P  
 635712-16-2P 635712-17-3P 635712-19-5P  
 635712-20-8P 635712-22-0P 635712-23-1P  
 635712-24-2P 635712-25-3P 635712-26-4P  
 635712-27-5P 635712-28-6P 635712-29-7P  
 635712-30-0P 635712-31-1P 635712-32-2P  
 635712-33-3P 635712-34-4P 635712-35-5P  
 635712-38-8P  
 (preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists for treating migraine and other diseases)  
 IT 635711-71-6P  
 (preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists for treating migraine and other diseases)  
 PN 635711-71-6 USPAT2  
 CN Urea, N-((1S)-1-((1,4'-bipiperidin)-1'-ylcarbonyl)-3-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl)-N'-2-naphthalenyl- (CA INDEX NAME)

Absolute stereochemistry.

L21 ANSWER 10 OF 11 USPAT2 on STN (Continued)



L21 ANSWER 11 OF 11 USPAT2 on STN  
 AN 2004361895 USPAT2  
 TI Calcitonin gene related peptide receptor antagonists  
 IN Chaturvedula, Prasad V., Cheshire, CT, UNITED STATES  
 Chen, Ling, Middletown, CT, UNITED STATES  
 Civilello, Rita, Killingworth, CT, UNITED STATES  
 Degnan, Andrew P., New Haven, CT, UNITED STATES  
 Dubowchik, Gene M., Middlefield, CT, UNITED STATES  
 Han, Xiaojun, Cheshire, CT, UNITED STATES  
 Jiang, Xiang Jun J., Hamden, CT, UNITED STATES  
 Karageorge, George N., Portland, CT, UNITED STATES  
 Luo, Guanglin, Madison, CT, UNITED STATES  
 Macor, John E., Guilford, CT, UNITED STATES  
 Poindexter, Graham, Old Saybrook, CT, UNITED STATES  
 Tora, George, Meriden, CT, UNITED STATES  
 PA Bristol-Myers Squibb Company, Princeton, NJ, UNITED STATES (U.S. corporation)  
 PI US--7220862 B2 20070522  
 AI 2003US-000729155 20031205 (10)  
 RLI Continuation-in-part of Ser. No. 2003US-000445523, filed on 27 May 2003, ABANDONED  
 PRAI 2002US-000413534P 20020925 (60)  
 2002US-000393200P 20020701 (60)  
 2002US-000389870P 20020619 (60)  
 2002US-00038617P 20020613 (60)  
 2002US-000386138P 20020605 (60)  
 DI Utility  
 FS GRANTED  
 EXRM Primary Examiner: Balasubramanian, Venkataraman  
 LREP Makujina, Shah R.  
 CLMN Number of Claims: 36  
 ECL Exemplary Claim: 1  
 DRMN 5 Drawing Figure(s); 5 Drawing Page(s)  
 LN.CNT 9261  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The present invention relates to compounds of Formula (I)

##STR1## as antagonists of calcitonin gene-related peptide receptors ("CGRP-receptor"), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 635711-71-6P 635711-72-7P 635711-73-8P  
 635711-75-0P 635711-76-1P 635711-77-2P  
 635711-78-3P 635711-79-4P 635711-80-7P  
 635711-82-9P 635711-83-0P 635711-84-1P  
 635711-86-3P 635711-87-4P 635711-88-5P  
 635711-89-6P 635711-90-9P 635711-91-0P  
 635711-92-1P 635711-93-2P 635711-94-3P  
 635711-95-4P 635711-96-5P 635711-97-6P  
 635711-98-7P 635711-99-8P 635712-00-4P  
 635712-01-5P 635712-02-6P 635712-04-8P  
 635712-05-9P 635712-08-2P 635712-09-3P  
 635712-10-6P 635712-11-7P 635712-12-8P  
 635712-13-9P 635712-14-0P 635712-15-1P  
 635712-16-2P 635712-17-3P 635712-19-5P  
 635712-20-8P 635712-22-0P 635712-23-1P  
 635712-24-2P 635712-25-3P 635712-26-4P  
 635712-27-5P 635712-28-6P 635712-29-7P  
 635712-30-0P 635712-31-1P 635712-32-2P  
 635712-33-3P 635712-34-4P 635712-35-5P  
 635712-38-8P


(preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists)

IT 635711-71-6P

L21 ANSWER 11 OF 11 USPAT2 on STN (Continued)

(prepn. of diazaheterocycles as calcitonin gene related peptide receptor antagonists)  
 RN 635711-71-6 USPAT2  
 CN Urea, N-[(1S)-1-[(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(3,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]-N'-2-naphthalenyl- (CA INDEX NAME)

Absolute stereochemistry.



=&gt; d his

(FILE 'HOME' ENTERED AT 14:02:25 ON 06 MAY 2008)

FILE 'HCAPLUS' ENTERED AT 14:03:03 ON 06 MAY 2008

L1 1 US20070123509/PN

FILE 'REGISTRY' ENTERED AT 14:03:18 ON 06 MAY 2008

FILE 'HCAPLUS' ENTERED AT 14:03:18 ON 06 MAY 2008

L2 TRA L1 1- RN : 72 TERMS

FILE 'REGISTRY' ENTERED AT 14:03:18 ON 06 MAY 2008

L3 72 SEA L2

L4 27 L3 AND &gt;=2 NC5/ES

L5 26 L4 AND NR&gt;=3

L6 STR

L7 0 L6

L8 419318 &gt;=2 NC5/ES

L9 83515 &gt;=2 46.156.1/RID

L10 0 L6 SAM SUB=L8

L11 101 L6 FULL SUB=L8

SAV TEM J850GI/A L11

L12 100 L11 AND L9

L13 1 L11 NOT L12

L14 24 L12 AND L3

L15 76 L12 NOT L14

FILE 'HCAPLUS' ENTERED AT 14:12:24 ON 06 MAY 2008

L16 2 L14

L17 8 L15

FILE 'HCAOLD' ENTERED AT 14:12:40 ON 06 MAY 2008

L18 0 L14

L19 0 L15

FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 14:12:51 ON 06 MAY 2008

L20 1 L14

L21 11 L15

=&gt;